Loading quotes...

Forecast

The analysts' average price target is €3.59 (+88.95%). The median is €3.59 (+88.95%).

Buy	6
Hold	1
Sell	0

News Go to news feed

Veru relies on muscle protection with Enobosarm to differentiate in obesity market

Veru presents data showing that Enobosarm combined with semaglutide preserves muscle function and lean mass in older patients and shifts weight loss toward fat. The fully recruited phase‑IIb PLATEAU study (239 patients, 68 weeks) will provide an interim analysis in Q1 2027; the aim is to prepare a phase‑III program with about 4,500 patients. Veru reports patent protection for the combination until 2044, a supply agreement with Novo Nordisk and roughly 24 million USD in cash, which should secure liquidity until mid‑2027, but it still faces the usual clinical, regulatory and financing risks. » More on de.investing.com
Veru beats EPS estimate in 3rd quarter; PLATEAU study fully recruited

Veru reported an adjusted loss of $0.30 per diluted share in the 3rd quarter, beating the consensus estimate of $0.31. Net loss narrowed versus the prior period, aided by a lower share count and reduced G&A expenses, while R&D spending for the PLATEAU study increased. The Phase IIb PLATEAU study is fully recruited with 239 patients and is scheduled to deliver a planned interim analysis in Q1 2027; cash of $23.9 million is expected to fund operations beyond that analysis. The stock reacted only slightly positive premarket and remains near its 52-week low. » More on de.investing.com
Veru rises sharply after supply agreement with Novo Nordisk

Veru announced an agreement with Novo Nordisk for the free supply of Wegovy for the Phase‑2b PLATEAU study, in which enobosarm is being tested together with semaglutide in older adults with obesity. Novo Nordisk secured a right of first negotiation for future commercial opportunities for the enobosarm‑GLP‑1 combination, which investors saw as a vote of confidence. The announcement led to heavy trading volume and an intraday jump in Veru’s stock of about 167%, as the program builds on positive QUALITY data and provides the small‑cap with substantial cost relief. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2010, Veru Inc has already paid €0.0364 in dividends. The last payout was in February 2010.

Financials

In the last quarter, Veru Inc had revenue of €0 and net profit of -€6.12m

(EUR)	June 2026	YoY
Revenue	0	-
Gross profit	0	-
Net profit	-6.12m	1.58%
EBITDA	-6.1m	10.17%

Fundamentals

Metric	Value
Market capitalization	€33.66m
Number of shares	17.05m
52-week high/low	€6.58 - €1.84
Dividends	No
Beta	-1.19
P/E ratio	-3.66
PEG ratio	-0.02
P/B ratio	1.79
P/S ratio	0.00

Company profile

Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

Name	Veru Inc
CEO	Mitchell S. Steiner
Headquarters	Miami, fl USA
Website	verupharma.com
Sector	Health Care
Industry	Health Care Technology
IPO	11/02/1999
Employees	20